1. Home
  2. TBPH vs DADA Comparison

TBPH vs DADA Comparison

Compare TBPH & DADA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TBPH
  • DADA
  • Stock Information
  • Founded
  • TBPH 2013
  • DADA 2014
  • Country
  • TBPH United States
  • DADA China
  • Employees
  • TBPH N/A
  • DADA N/A
  • Industry
  • TBPH Biotechnology: Pharmaceutical Preparations
  • DADA Computer Software: Programming Data Processing
  • Sector
  • TBPH Health Care
  • DADA Technology
  • Exchange
  • TBPH Nasdaq
  • DADA Nasdaq
  • Market Cap
  • TBPH 464.5M
  • DADA 482.9M
  • IPO Year
  • TBPH N/A
  • DADA 2020
  • Fundamental
  • Price
  • TBPH $9.30
  • DADA $1.88
  • Analyst Decision
  • TBPH Buy
  • DADA Hold
  • Analyst Count
  • TBPH 3
  • DADA 3
  • Target Price
  • TBPH $11.33
  • DADA $2.67
  • AVG Volume (30 Days)
  • TBPH 224.8K
  • DADA 2.8M
  • Earning Date
  • TBPH 05-12-2025
  • DADA 05-14-2025
  • Dividend Yield
  • TBPH N/A
  • DADA N/A
  • EPS Growth
  • TBPH N/A
  • DADA N/A
  • EPS
  • TBPH N/A
  • DADA N/A
  • Revenue
  • TBPH $64,381,000.00
  • DADA $1,323,968,707.00
  • Revenue This Year
  • TBPH $51.09
  • DADA $12.85
  • Revenue Next Year
  • TBPH N/A
  • DADA $12.25
  • P/E Ratio
  • TBPH N/A
  • DADA N/A
  • Revenue Growth
  • TBPH 12.12
  • DADA N/A
  • 52 Week Low
  • TBPH $7.44
  • DADA $1.04
  • 52 Week High
  • TBPH $10.90
  • DADA $2.52
  • Technical
  • Relative Strength Index (RSI)
  • TBPH 58.45
  • DADA 47.85
  • Support Level
  • TBPH $8.44
  • DADA $1.85
  • Resistance Level
  • TBPH $8.82
  • DADA $1.89
  • Average True Range (ATR)
  • TBPH 0.45
  • DADA 0.02
  • MACD
  • TBPH 0.08
  • DADA -0.01
  • Stochastic Oscillator
  • TBPH 94.70
  • DADA 18.75

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About DADA Dada Nexus Limited

Dada Nexus provides on-demand retail platform services and fulfillment services to retailers to sell their products, and online advertising and marketing services to its customers such as brand owners or their agents. It also provides last-mile, intracity and intercity delivery services to logistics companies, merchants and individuals on the Dada Now platform. The group fulfills the delivery needs of retailers on JD Now and customers on Dada Now mostly by utilizing registered riders on Dada Now. Dada's average delivery time for on-demand intracity delivery orders was within 30 minutes in 2023, faster than traditional e-commerce where delivery can take days. As of Sept. 16, 2024, JD.com owned 63.2% of Dada Nexus. Dada Nexus competes with Meituan, Ele.me, Douyin, and SF Intra-city.

Share on Social Networks: